Chikungunya: Clearing the Final Hurdle

The search for a vaccine against disabling chikungunya virus, endemic among 1.3 billion people living in the tropics and sub-tropics, is moving full speed ahead.
With promising options in the pipeline—including a modified measles vaccine—epidemiologists, vaccine developers and regulators convened in New Delhi this week to evaluate how to move a vaccine to market.
But chikungunya’s “epidemic nature,” writes Declan Butler, poses a challenge to getting a vaccine through phase-3 trials—the final hurdle to licensing—which would involve rounding up thousands of volunteers in at-risk areas. But the right vaccine may be allowed to skip this stage, given the medical need.

Secondary Topic
Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top